Riskpilot← Back to searchSign inGet full accessMNA Läkarkonsult AB
ABActiveOrg 5590416110Hornsbergs Strand 43Medical specialists activities · NACE 8622Est. 20152 employees
Revenue 2024
SEK 2,2M
+25% vs 2023
EBITDA margin
64.3%
+24% vs 2023
Equity ratio
93.8%
Financial strength
Net profit 2024
SEK 1,1M
+23% vs 2023
| Revenue | SEK 2,2M | +25% |
| EBITDA | SEK 1,4M | +24% |
| Net profit | SEK 1,1M | +23% |
| Total assets | SEK 8,9M | +16% |
| Equity | SEK 8,3M | +13% |
| Employees | 2 | — |
Legal name
MNA Läkarkonsult AB
Org number
5590416110
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
15 december 2015
Share capital
SEK 50 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet skall vara att tillhandahålla läkarkompetens inom psykiatri, primärvård och företagshälsovård samt därmed förenlig verksamhet. Bolaget kommer att ordna föreläsningar och utbildningar inom ovanstående områden samt därmed förenlig verksamhet. Bolaget skall idka handel med värdepapper och fastigheter.
Address
Hornsbergs Strand 43
Email
murad.ahmad@live.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 2 298 | 2 118 | 1 617 | 1 731 | 2 166 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 2 022 | 1 539 | 1 122 | 1 119 | 1 393 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 2 022 | 1 539 | 1 122 | 1 119 | 1 393 |
| Net financials | −4 | — | — | 53 | 54 |
| Profit before tax | 2 018 | 1 539 | 1 123 | 1 173 | 1 446 |
| Tax | −445 | −289 | −232 | −243 | −299 |
| Net profit | 1 573 | 1 250 | 891 | 930 | 1 147 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 5 579 | 6 315 | 6 890 | 7 687 | 8 881 |
| Equity | 4 883 | 5 948 | 6 650 | 7 385 | 8 328 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 696 | 368 | 240 | 302 | 552 |
| Total debt | 696 | 368 | 240 | 302 | 552 |
EBITDA margin
64.3%
This company
15.8%
Market median
+307% vs market
20202024
Equity ratio
93.8%
This company
38.2%
Market median
+146% vs market
20202024
Return on equity
13.8%
This company
18.4%
Market median
+25% vs market
20202024
Net profit margin
53.0%
This company
8.1%
Market median
+554% vs market
20202024
Asset turnover
0.24×
This company
1.12×
Market median
-79% vs market
20202024
Debt / equity
0.07×
This company
0.62×
Market median
+89% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2022 | |
| Chairman | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of MNA Läkarkonsult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hammad Nadeem Ahmad | Deputy Board Member | 0 companies |
| Medina Hajric | Chairman | 0 companies |
| Murad Nadeem Ahmad | Board of Directors | 0 companies |